TY - JOUR
T1 - Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial
AU - Cukierman-Yaffe, Tali
AU - Gerstein, Hertzel C.
AU - Basile, Jan
AU - Angelyn Bethel, M.
AU - Cardona-Munoz, Ernesto G.
AU - Conget, Ignacio
AU - Dagenais, Gilles
AU - Franek, Edward
AU - Hall, Stephanie
AU - Hancu, Nicolae
AU - Jansky, Petr
AU - Lakshmanan, Mark
AU - Lanas, Fernando
AU - Leiter, Lawrence A.
AU - Lopez-Jaramillo, Patricio
AU - Pirags, Valdis
AU - Pogosova, Nana
AU - Probstfield, Jeffrey
AU - Rao-Melacini, Purnima
AU - Ramasundarahettige, Chinthanie
AU - Raubenheimer, Peter J.
AU - Riddle, Matthew C.
AU - Ryden, Lars
AU - Shaw, Jonathan E.
AU - Sheu, H. H.
AU - Temelkova-Kurktschiev, Theodora
N1 - Publisher Copyright:
© 2022 Endocrine Society. All rights reserved.
PY - 2022/8/1
Y1 - 2022/8/1
N2 - Context: Low cognitive scores are risk factors for cardiovascular outcomes. Whether this relationship is stronger using novel cognitive indices is unknown. Methods: Participants in the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial who completed both the Montreal Cognitive Assessment (MoCA) score and Digit Substitution Test (DSST) at baseline (N = 8772) were included. These scores were used to identify participants with baseline substantive cognitive impairment (SCI), defined as a baseline score on either the MoCA or DSST ≥ 1.5 SD below either score's country-specific mean, or SCI-GM, which was based on a composite index of both scores calculated as their geometric mean (GM), and defined as a score that was ≥ 1.5 SD below their country's average GM. Relationships between these measures and incident major adverse cardiovascular events (MACE), and either stroke or death were analyzed. Results: Compared with 7867 (89.7%) unaffected participants, the 905 (10.3%) participants with baseline SCI had a higher incidence of MACE (unadjusted hazard ratio [HR] 1.34; 95% CI 1.11, 1.62; P = 0.003), and stroke or death (unadjusted HR 1.60; 95% CI 1.33, 1.91; P < 0.001). Stronger relationships were noted for SCI-GM and MACE (unadjusted HR 1.61; 95% CI 1.28, 2.01; P < 0.001), and stroke or death (unadjusted HR 1.85; 95% CI 1.50, 2.30; P < 0.001). For SCI-GM but not SCI, all these relationships remained significant in models that adjusted for up to 10 SCI risk factors. Conclusion: Country-standardized SCI-GM was a strong independent predictor of cardiovascular events in people with type 2 diabetes in the REWIND trial.
AB - Context: Low cognitive scores are risk factors for cardiovascular outcomes. Whether this relationship is stronger using novel cognitive indices is unknown. Methods: Participants in the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial who completed both the Montreal Cognitive Assessment (MoCA) score and Digit Substitution Test (DSST) at baseline (N = 8772) were included. These scores were used to identify participants with baseline substantive cognitive impairment (SCI), defined as a baseline score on either the MoCA or DSST ≥ 1.5 SD below either score's country-specific mean, or SCI-GM, which was based on a composite index of both scores calculated as their geometric mean (GM), and defined as a score that was ≥ 1.5 SD below their country's average GM. Relationships between these measures and incident major adverse cardiovascular events (MACE), and either stroke or death were analyzed. Results: Compared with 7867 (89.7%) unaffected participants, the 905 (10.3%) participants with baseline SCI had a higher incidence of MACE (unadjusted hazard ratio [HR] 1.34; 95% CI 1.11, 1.62; P = 0.003), and stroke or death (unadjusted HR 1.60; 95% CI 1.33, 1.91; P < 0.001). Stronger relationships were noted for SCI-GM and MACE (unadjusted HR 1.61; 95% CI 1.28, 2.01; P < 0.001), and stroke or death (unadjusted HR 1.85; 95% CI 1.50, 2.30; P < 0.001). For SCI-GM but not SCI, all these relationships remained significant in models that adjusted for up to 10 SCI risk factors. Conclusion: Country-standardized SCI-GM was a strong independent predictor of cardiovascular events in people with type 2 diabetes in the REWIND trial.
KW - Cardiovascular events
KW - Cognitive impairment
KW - Composite outcome
KW - Death
KW - Geometric mean
KW - MACE
KW - Risk factor
KW - Stroke
UR - http://www.scopus.com/inward/record.url?scp=85134434621&partnerID=8YFLogxK
U2 - 10.1210/clinem/dgac200
DO - 10.1210/clinem/dgac200
M3 - Artículo Científico
C2 - 35446415
AN - SCOPUS:85134434621
SN - 0021-972X
VL - 107
SP - E3448-E3454
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 8
ER -